Skip to main content

Safety and efficacy of blinatumomab: a real world data

Abstract

Despite improvement in survival of newly diagnosed adult precursor B-acute lymphoblastic leukemia/lymphoma (B-ALL), the results of relapsed/refractory disease are poor. Blinatumomab, a bispecific monoclonal antibody directed against CD19/CD3 show clinical activity against relapsed/refractory B-ALL and in minimal residual disease (MRD)-positive patients.

We report our “real-world” experience with blinatumomab in patients with relapsed/refractory B-ALL.

Twenty-one patients, at a median age 52 years with median disease duration of 10 months, were included. Indications for treatment were hematological relapse (n = 17), MRD positivity (n = 2), inability to continue intensive chemotherapy (n = 1), and bridging to a second alloSCT (n = 1). Blinatumomab was given as first salvage in 11 patients and after at least one prior salvage treatment in eight.

Complete response (CR) was newly achieved in 47% and was maintained in 75% of patients with baseline CR. At a median follow-up of 12.4 months, 13 patients were alive, and 11 in CR. Median leukemia-free survival was 8.7 months, and median overall survival was 15.2 months. Median leukemia-free survival and overall survival were not reached in patients proceeding to alloSCT compared to 5.1 and 15.2 months, respectively, for patients who did not receive stem cell transplantation.

Treatment was well tolerated with neurological events reported in two patients (10%) and GI events in three patients (14%). Cytokine storm was reported in four patients (19%).

In conclusion, treatment with blinatumomab is effective and tolerable in adult patients with relapsed/refractory B-ALL outside of a clinical trial stetting.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Strack M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120(10):2032–2041. https://doi.org/10.1182/BLOOD-2011-12-399287

    Article  PubMed  Google Scholar 

  2. 2.

    Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foa R, Bassan R, Arslan O, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Bruggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman TMS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836–847. https://doi.org/10.1056/NEJMoa1609783

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Bruggemann M, Horst HA, Havelange, Stieglmaier J, Wessels H, Hassas V, Benjamin JE, Zugmaier G, Nagorsen D, Barou RC (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522–1531. https://doi.org/10.1182/blood-2017-08-798322

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Kantarjian HM, DeAmgelo DJ, Stelljes G, Martinelli G, Liedtke M, Stock W, Gokbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740–753. https://doi.org/10.1056/NEJMoa1509277

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M (2018) Long term follow up of C19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449–459. https://doi.org/10.1056/NEJMoa1709919

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B cell lymphoblastic leukemia. N Engl J Med 378(5):439–448. https://doi.org/10.1056/NEJMoa1709866

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Jung SH, Lee SR, Yang AH, Lee S, Yoon JH, Lee H, Bang SM, Koh Y, Park S, Kin DS, Thim HY, Lee JH, Sohn SK, Song IC, Lee HG, Cheong JW, Choi Y, Shin HJ (2019) Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. Ann Hematol 98:151–158. https://doi.org/10.1007/s00277-018-3495-2

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Topp MA, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A, Franklin J, Tran Q, Cong Z, Schuh AC (2018) Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood 131(26):2906–2914. https://doi.org/10.1182/blood-2017-09-804658

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Arie Apel.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Since this is a retrospective data collection, a waiver from informed consent was received from the local IRB.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Apel, A., Ofran, Y., Wolach, O. et al. Safety and efficacy of blinatumomab: a real world data. Ann Hematol 99, 835–838 (2020). https://doi.org/10.1007/s00277-019-03854-0

Download citation

Keywords

  • Blinatumomab
  • Precursor B-acute lymphoblastic leukemia/lymphoma
  • Minimal residual disease
  • Salvage therapy